151 related articles for article (PubMed ID: 37812756)
1. Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.
Singer EA; Rumble RB; Rathmell WK; Van Veldhuizen PJ;
J Clin Oncol; 2023 Nov; 41(33):5184-5186. PubMed ID: 37812756
[No Abstract] [Full Text] [Related]
2. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.
Roeland EJ; Bohlke K; Baracos VE; Smith TJ; Loprinzi CL;
J Clin Oncol; 2023 Sep; 41(25):4178-4179. PubMed ID: 37467399
[No Abstract] [Full Text] [Related]
3. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Singh N; Daly ME; Ismaila N;
J Clin Oncol; 2023 Sep; 41(27):4430-4432. PubMed ID: 37471673
[No Abstract] [Full Text] [Related]
4. Systemic Therapy Update on
Garje R; Rumble RB; Parikh RA;
J Clin Oncol; 2023 Nov; ():JCO2302128. PubMed ID: 37931186
[No Abstract] [Full Text] [Related]
5. Testing for
Burstein HJ; DeMichele A; Somerfield MR; Henry NL;
J Clin Oncol; 2023 Jun; 41(18):3423-3425. PubMed ID: 37196213
[No Abstract] [Full Text] [Related]
6. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
Freedman RA; Caswell-Jin JL; Hassett M; Somerfield MR; Giordano SH;
J Clin Oncol; 2024 Jun; 42(18):2233-2235. PubMed ID: 38768407
[No Abstract] [Full Text] [Related]
7. Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Burstein HJ; DeMichele A; Fallowfield L; Somerfield MR; Henry NL; ;
J Clin Oncol; 2024 Apr; 42(12):1450-1453. PubMed ID: 38478799
[No Abstract] [Full Text] [Related]
8. Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
Seth R; Messersmith H; Funchain P;
J Clin Oncol; 2022 Jul; 40(21):2375-2377. PubMed ID: 35658488
[No Abstract] [Full Text] [Related]
9. Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update.
Chuang LT; Temin S; Berek JS;
JCO Glob Oncol; 2022 Mar; 8():e2200027. PubMed ID: 35245079
[No Abstract] [Full Text] [Related]
10. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
Tew WP; Lacchetti C; Kohn EC;
J Clin Oncol; 2022 Nov; 40(33):3878-3881. PubMed ID: 36150092
[No Abstract] [Full Text] [Related]
11. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Moy B; Rumble RB; Carey LA;
J Clin Oncol; 2023 Feb; 41(6):1318-1320. PubMed ID: 36626701
[No Abstract] [Full Text] [Related]
12. Systemic Therapy Update on
Garje R; Rumble RB; Parikh RA
J Clin Oncol; 2022 Nov; 40(31):3664-3666. PubMed ID: 36112960
[No Abstract] [Full Text] [Related]
13. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
Moy B; Rumble RB; Carey LA;
J Clin Oncol; 2022 Sep; 40(26):3088-3090. PubMed ID: 35926153
[No Abstract] [Full Text] [Related]
14. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Korde LA; Somerfield MR; Hershman DL;
J Clin Oncol; 2022 May; 40(15):1696-1698. PubMed ID: 35417251
[No Abstract] [Full Text] [Related]
15. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Pisters K; Kris MG; Gaspar LE; Ismaila N;
J Clin Oncol; 2022 Apr; 40(10):1127-1129. PubMed ID: 35167335
[No Abstract] [Full Text] [Related]
16. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
Shah MA; Hofstetter WL; Kennedy EB;
J Clin Oncol; 2021 Oct; 39(28):3182-3184. PubMed ID: 34406872
[No Abstract] [Full Text] [Related]
17. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline
Tung NM; Zakalik D; Somerfield MR;
J Clin Oncol; 2021 Sep; 39(26):2959-2961. PubMed ID: 34343058
[No Abstract] [Full Text] [Related]
18. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
Giordano SH; Freedman RA; Somerfield MR;
J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
[No Abstract] [Full Text] [Related]
19. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3.
Jaiyesimi IA; Owen DH; Ismaila N; Blanchard E; Celano P; Florez N; Jain D; Singh N
J Clin Oncol; 2023 Apr; 41(11):e31-e41. PubMed ID: 36802359
[No Abstract] [Full Text] [Related]
20. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1.
Singh N; Jaiyesimi IA; Ismaila N; Leighl NB; Mamdani H; Phillips T; Owen DH
J Clin Oncol; 2023 May; 41(15):e42-e50. PubMed ID: 37023367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
